EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
Australian Consumer Sentiment Slumps in Early December as Inflation Fears Resurface 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
